Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.
| Market Capitalization | $12.274 million |
| P/E Ratio | 0 |
| P/E Growth Ratio | |
| Book Value | 0.031 |
| Dividend Per Share | 0 |
| Earnings Per Share | -0.05 |
| EBITDA | -10,490.372 |
| Profit Margin | -2.5052 |
| Operating Margin TTM | -1.7712 |
| Return on Assets TTM | -0.3623 |
| Return on Equity TTM | -0.9073 |
| Revenue TTM | 6,010.086 |
All numbers are in thousands
| Date | Total Revenue | Cost of Revenue | Gross Profit | Total Operating Expenses |
|---|---|---|---|---|
| 2016-06-30 | 0.36 | 0 | 0 | 1,054.601 |
| 2017-06-30 | 193.8 | 0 | 126.299 | 3,239.703 |
| 2018-06-30 | 979.34 | 0 | 916.534 | 10,508.215 |
| 2019-06-30 | 3,937.36 | 3,750.675 | 15,680.34 | |
| 2020-06-30 | 8,343.56 | 16,366.388 | ||
| 2021-06-30 | 5,747.72 | 20,214.065 | ||
| 2022-06-30 | 5,450.59 | 15,207.681 | ||
| 2023-06-30 | 6,067.6 |
All numbers are in thousands
| Date | Cash | Total Assets | Total Liabilities | Short Term Debt | Long Term Debt | Common Stock |
|---|---|---|---|---|---|---|
| 2016-06-30 | 6,177.623 | 6,207.723 | 261.72 | 6,352.056 | ||
| 2017-06-30 | 2,457.848 | 2,828.556 | 361.042 | 0 | 6,218.14 | |
| 2018-06-30 | 12,613.534 | 14,549.329 | 4,401.363 | 3,279.452 | 3,279.45 | 28,449.283 |
| 2019-06-30 | 2,909.568 | 4,300.407 | 5,750.876 | 3,930.351 | 0 | 28,700.897 |
| 2020-06-30 | 7,100.202 | 20,067.151 | 7,194.393 | 4,586.82 | 41,631.007 | |
| 2021-06-30 | 26,795.785 | 47,853.711 | 7,077.336 | 231.666 | 72,622.56 | |
| 2022-06-30 | 14,010.668 | 26,593.757 | 2,475.813 | 160.624 | 74,635.721 | |
| 2023-06-30 | 3,008.674 | 10,128.45 | 1,055.189 | 0 | 74,635.721 |
All numbers are in thousands
| Date | Net Income | Total Cash | Change in Cash | Begin period cash | End period cash | Dividends |
|---|---|---|---|---|---|---|
| 2016-06-30 | -1,057.088 | -549.72 | 160.96 | 160.96 | ||
| 2017-06-30 | -3,045.901 | -2,917.966 | 2,296.888 | 160.96 | 2,457.848 | 0 |
| 2018-06-30 | -18,283.501 | -9,075.628 | 10,155.686 | 2,457.848 | 12,613.534 | |
| 2019-06-30 | -11,222.787 | -9,775.765 | -9,703.966 | 12,613.534 | 2,909.568 | |
| 2020-06-30 | -272.093 | -11,137.958 | 4,190.634 | 2,909.568 | 7,100.202 | -9,696.976 |
| 2021-06-30 | -11,532.97 | -8,850.441 | 19,695.583 | 7,100.202 | 26,795.785 | |
| 2022-06-30 | -18,744.145 | -18,482.632 | -12,785.117 | 26,795.785 | 14,010.668 | |
| 2023-06-30 | -15,056.373 | -10,946.345 | -11,001.994 | 14,010.668 | 3,008.674 |